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West Nile virus (WNV) is continuously spreading 
across Europe, and other continents, i.e. North and 
South America and many other regions of the world. 
Despite the overall sporadic nature of outbreaks with 
cases of West Nile neuroinvasive disease (WNND) in 
Europe, the spillover events have increased and the 
virus has been introduced into new areas. The high 
genetic diversity of the virus, with remarkable pheno-
typic variation, and its endemic circulation in several 
countries, require an intensification of the integrated 
and multidisciplinary research efforts built under the 
7th Framework Programme of the European Union 
(FP7). It is important to better clarify several aspects 
of WNV circulation in Europe, including its ecology, 
genomic diversity, pathogenicity, transmissibility, 
diagnosis and control options, under different envi-
ronmental and socio-economic scenarios. Identifying 
WNV endemic as well as infection-free areas is becom-
ing a need for the development of human vaccines and 
therapeutics and the application of blood and organs 
safety regulations. This review, produced as a joint ini-
tiative among European experts and based on analysis 
of 118 scientific papers published between 2004 and 
2014, provides the state of knowledge on WNV and 
highlights the existing knowledge and research gaps 
that need to be addressed with high priority in Europe 
and neighbouring countries. 
Introduction
West Nile virus (WNV) is an African flavivirus originally 
maintained in sylvatic cycles mostly between mos-
quitoes and birds. Since the 1950s, there has been 
evidence of circulation outside its original ecologi-
cal niches [1]. Relatively large outbreaks of West Nile 
neuroinvasive disease (WNND) have been recorded 
in humans and/or horses in an increasing number of 
areas. WNV infections have been identified in many 
European and Mediterranean countries (Figure 1) [1,2]. 
The increasing incidence of WNND, the appearance of 
new foci, and the endemic virus circulation in temperate 
areas have promoted research and innovation efforts 
financially supported by the European Commission (EC) 
under the 7th Framework Programme (FP7). However, 
knowledge gaps remain on several important aspects 
of virus ecology, biology, and pathogenicity. Together 
with the lack of safe vaccines and specific therapeutic 
treatments for humans, this limits our ability to effi-
ciently predict, prevent and control WNV infections, 
with increasing costs due to the needs of guarantee 
the safety of blood transfusion and organ donation [3]. 
There are also rising problems associated with the loss 
in efficacy and increased resistance to many commer-
cial insecticidal products used to suppress mosquito 
populations [4]. This requires the intensification of 
research efforts for emerging vector-borne infections, 
such as those caused by WNV and other flaviviruses, 
and the maintenance of the existing research capacity.
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Therefore, the coordinators and representative mem-
bers of four EC FP7 European funded projects on WNV 
and other mosquito-borne viral diseases (EuroWestNile, 
EDENext, Wings, Vectorie) met in Madrid on several 
occasions to review and discuss WNV knowledge 
advances and identify research gaps to be addressed, 
under a ‘One Health’ perspective, with high priority.
Methods
The expert group integrated their expert knowledge 
and opinion with a scientific literature review. Following 
a search in the databases ISI Web of Knowledge and 
PubMed, using defined qualifiers for the viral infection 
[(WNV)], the disease [(WNND)], host [(humans], [birds], 
[horses)], geographical location [(Africa], [Europe], 
[Mediterranean basin)] and issue [(virology], [genom-
ics], [epidemiology], [ecology], [pathology], [diagnos-
tics], [vaccine], [control], [review]). In the search, the 
period of publication was limited to publications from 
January 2004 to October 2014. Inclusion criteria were 
based on title, abstract and year of publication, lead-
ing, if relevant to the above mentioned qualifiers, 
to retrieval and analysis of the full paper. Exclusion 
criteria were based on the year of publication and 
on the novelty of the information provided choosing 
those most up to date on the same subject and those 
including the previous in the reference list. Only arti-
cles with the latest findings on a specific subject were 
included and those older than the period covered were 
discarded.
A total of 118 scientific publications were then chosen 
among the 513 initially retrieved.
Epidemiology of West Nile virus in Europe 
and neighbouring countries
Circulating West Nile virus strains
The re-emergence of WNV in Europe and neighbour-
ing countries after 1990 led to an intensified surveil-
lance for WNV infection not only in humans, but also 
in horses, birds, and mosquitoes in several areas. This 
has resulted in the detection and/or isolation of many 
different strains of WNV, eventually classified as up to 
seven (nine) different genetic lineages [5-10] (Table 1, 
Figure 2 A-C). There is a growing number of WNV lin-
eages and to address inconsistent numbering in the 
literature we suggest in Table 1 and Figure 2 a harmo-
nised WNV lineage numbering. 
The most widespread WNV lineages include lineage 
1, clade 1a, belonging to the Mediterranean and for-
mer eastern European subtype, and lineage 2, which 
emerged in central Europe in 2004, and dispersed from 
Hungary to the eastern part of Austria and to southern 
European countries [11,12]. Following an independent 
introduction, another lineage 2 strain was detected 
in 2004 in Rostov Oblast, southern Russia [13]; sub-
sequently, this virus strain has been responsible for 
outbreaks of WNND in Volgograd Oblast southern 
Russia since 2007, and in Romania since 2010 [14,15]. 
Phylogenetic analyses revealed that all European WNV 
lineage 1 and 2 strains are derived from a limited num-
ber of independent introductions, most likely from 
Africa, followed by local spread and evolution [5,15-
20]. Other lineages identified but not associated so far 
with human or animal diseases include WNV lineage 3, 
also known as Rabensburg virus, first isolated in 1997 
in South Moravia (Czech Republic) in Culex pipiens 
and Aedes rossicus mosquitoes in Czech Republic, and 
named after the nearby Austrian city of Rabensburg 
[6], WNV lineage 4a, Krasnodar virus, first detected in 
a Dermacentor tick and then in mosquitoes and frogs 
in southern Russia [7], putative WNV lineage 4b, iden-
tified in 2010 mosquitoes in southern Spain [8], and 
lineage 4c detected in Uranotaenia unguiculata mos-
quitoes in Austria in 2013 [9].
In recent years, the availability of whole WNV genome 
sequences of European origin, necessary for diagnos-
tic and molecular epidemiology and for better refining 
WNV taxonomic classification, has improved. A WNV 
strain bank and associated large genomic database 
has been built by the EuroWestNile consortium to 
facilitate this availability. The biobank and database 
are now available for the scientific community (www.
eurowestnile.org). 
Analyses of full genome sequence data have shown 
that the virus, notwithstanding its high genetic sta-
bility, can adapt to new ecological niches through 
mutation and selection events [21]. In addition to this 
plasticity, the presence of other flaviviruses infecting 
mosquitoes, birds and humans, may have important 
consequences not only for WNV ecology, epidemiology 
and pathogenicity, but also for diagnostics, surveil-
lance and control strategies [22].
West Nile lineages and human cases
Most humans infected with WNV remain asymptomatic 
and only approximately 20–40% develop symptoms. 
The vast majority of clinical manifestations are a mild 
influenza-like illness, defined as West Nile fever (WNF); 
severe neuroinvasive disease (WNND) occurs only in 
<1% of the infected patients. WNND usually encom-
passes three different syndromes: meningitis, enceph-
alitis, and acute flaccid paralysis [2 and references 
herein]. According to the European Centre for Disease 
Prevention and Control (ECDC), the total number of 
WNND cases reported from 2010 to 2013 was particu-
larly high in Greece, with 262 cases of WNND notified in 
2010 (incidence 2.34/100,000), 100 in 2011 (incidence 
0.90/100,000), 161 in 2012 (incidence 1.45/100,000), 
and 86 in 2013 (incidence 0.78/100,000) (unpublished 
data). 
WNV lineage 2 strains belonging to the Hungarian clade 
were responsible for the outbreaks in Greece [23,24] 
and in other central European countries, including 
Serbia [25-27], where 71 (incidence 0.98/100,000) and 
302 (incidence 4.91/100,000) human infections were 
notified in 2012 and 2013, respectively. Autochthonous 
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human cases of infection with this WNV strain were 
identified in recent years in Hungary, Austria [28], 
Croatia [29,30], Albania, the former Yugoslav Republic 
of Macedonia, Kosovo* and Montenegro. Closely 
related WNV lineage 2 strains of the same Hungarian 
clade have also been detected in Italy since 2011 [31-
33], leading to a large outbreak with 69 notified human 
infections (incidence 0.12/100,000) in 2013 [34], and 
in the Czech Republic in 2013 [35]. The epidemiologi-
cal situation in Italy is, however, more complex than 
in other countries [36]. WNV lineage 1 strains of the 
western Mediterranean subtype, including the Livenza 
strain that caused an outbreak in the area in northern 
Italy in 2012 [19,37] that was later affected by the WNV 
lineage 2 strain in 2013, have been autochthonous in 
Italy and co-circulate with WNV lineage 2. WNV lineage 
1 strains classified as western Mediterranean subtype 
circulated also in southern Spain [20], where sporadic 
human infections were reported in 2010. 
In Turkey, human cases of WNV infection were reported 
in 2010 (47 cases, incidence 0.06/ 100,000) and in 2011 
(five cases, incidence 0.01/100,000) [38]. WNV strains 
obtained between 2011 and 2013 from humans, horses 
and mosquitoes across Turkey proved to be closely 
related to ‘old’ lineage 1 strains from sub-Saharan 
Africa [39]. Israel, a highly WNV-affected Mediterranean 
country [40], noted over 100 cases diagnosed in 2010, 
33 in 2011, 83 in 2012, and 63 in 2013 (incidence rates 
per 100,000 not available) [40]. Finally, the southern 
Russian/Romanian WNV lineage 2 strain [15] has led to 
large outbreaks of WNND in humans in southern Russia 
in each season from 2010 to 2013 (419 cases in 2010, 
137 in 2011, 447 in 2012, and 177 in 2013, incidences 
rates per 100,000 not available), and in 2010 Romania, 
when 57 human infections (incidence 0.28/100,000) 
were identified [14].
Ecology
Mosquito vectors
Several mosquito genera are competent for WNV trans-
mission; however, mosquitoes belonging to the Culex 
pipiens complex and their hybrids play a central role 
in modulating the virus circulation and the seasonal 
shifts among birds and humans [41]. In addition to Cx. 
pipiens, Cx. perexiguus and Cx. modestus have been 
identified as important WNV vectors [42], while the role 
of other species, including the Aedes albopictus, needs 
to be better evaluated.
Introduction, transmission and spread
Introduction of WNV into new areas is generally con-
sidered to be initiated by migratory birds while resi-
dential and synanthropic birds may contribute to virus 
dispersal into larger areas, as well as to the following 
establishment and spread in certain areas [43,44]. 
However, the relative importance of dispersal of WNV 
through infected mosquitoes rather than by infected 
birds is unknown. The introduction event may or may 
not be followed by an amplification phase depending 
on several coincidental factors, ranging from the birds’ 
and vectors’ competence, abundance and community 
assembly, to the local environmental condition includ-
ing climate and landscape features [45-47]. One recog-
nised important factor for WNV amplification and the 
following risk of transmission to humans is the feed-
ing behaviour and host selection by the mosquito vec-
tors. Based on preliminary research carried out in Italy 
and Spain, only few bird species seem to play a major 
role as blood donor for the mosquitoes [42,48,49]. 
Unfortunately, the reservoir competence for many 
European bird species is still unknown. Furthermore, 
mass mortality of highly susceptible species (such as 
corvids or other species) is less frequently observed 
in the Old than in the New World although some spe-
cies, as the jackdaws (Corvus monedula) or other could 
potentially function as sentinel [50].
Virus persistence, silent circulation and 
spillover
Mechanisms of virus persistence in animal hosts in 
Europe are still unknown, but they could possibly lead 
to the development of persistent, chronic infections in 
certain individuals as seen in studies carried out in the 
United States [43,51]. In fact, in the New World, WNV, 
once established, circulates in enzootic cycles among 
few most competent mosquito species and their pre-
ferred feeding hosts [43,48,51]. The circulation of WNV 
in Europe may occur silently for several months, or 
even years, before the spillover event occurs [52]. One 
or more bird species may be involved in the amplifica-
tion chain, some being important in the maintenance 
of the sylvatic cycles, while others (that might not be 
the same) may be involved in the periurban and urban 
cycles. Following spillover and following outbreak a 
subsidence phase may occur as a consequence of 
the rise of herd immunity in the reservoir birds, that 
is dependent on host longevity and the rate of recruit-
ment of young individuals into the host population 
or the depopulation of highly susceptible bird hosts 
[43,51]. Unfortunately, the knowledge on herd immu-
nity to WNV for many bird species of the Old World is 
still lacking.
WNV diversity and interactions with other 
flaviviruses
A wide spectrum of WNV lineages and strains with 
different potential pathogenicity and virulence thrive 
among other related flaviviruses with overlapping 
ecology such as Bagaza virus (BAGV) and Usutu virus 
(USUV)[52,53]. In this scenario, a previous infection of 
the WNV amplifying bird hosts with a low pathogenic 
strain of WNV or with a closely related flavivirus may 
confer some degree of cross-immunity which might 
reduce the amplification of any new WNV strain intro-
duced into the same area [22]. This may explain, for 
instance, the scarcity of human WNV cases detected in 
Spain, where rates of WNV infection in birds are high 
and that may be due to the co-circulation of WNV line-
age 6 [8] or other flaviviruses, that induce the produc-
tion of potentially cross-protective antibodies in both 
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humans and birds, as reported for example for USUV 
[54].
However, co-infection may occur also in the mosquito 
vectors and therefore WNV replication could be in 
some way affected by previous infection with other 
co-circulating flaviviruses of the same antigenic group 
or even more distant viruses so that the epidemiologi-
cal picture may change from one site area to another 
[55]. Although some investigations on viral interference 
have been started with one project (EuroWestNile), we 
are still at the beginning of our understanding of the 
consequences of viral co-infections both in the host 
and in the vectors, and therefore research in this field 
is now of high interest.
Consequences for WNV surveillance in Europe
Passive surveillance programmes focusing only on 
the analysis of dead birds may fail to detect ongoing 
WNV circulation in Europe. It is advisable to combine 
conventional surveillance activities with actively moni-
toring seroconversion in sentinel and/or wild resident 
birds and horses [56-59].
Pathogenicity and other phenotypic traits
Studies using animal models, mainly mice, have pro-
vided insights into WNV pathogenesis. Intra-peritoneal 
injection of WNV into mice generally leads to enceph-
alitis and other neurological signs resembling those 
observed in humans with WNND [60]. This model 
provides researchers with a simple method enabling 
phenotypic characterisation of WNV strains for neu-
ropathogenicity and neuroinvasiveness. Through the 
integration of this information with analysis of genetic 
changes occurring in field WNV isolates and reverse 
genetics using infectious clones, molecular chimeras 
or other strategies, it is possible to identify determi-
nants of virulence [61-63]. However, the mouse model 
has important limitations and thus alternative animal 
models are highly desirable. An attempt of this kind, 
using one day old chickens, has recently been reported 
[64]. In addition, bird models of WNV infection provide 
information about the course of the infection in natu-
ral hosts [65 and references herein] and, consequently, 
about key aspects of WNV epidemiology. 
Genetic changes in different geographic WNV variants 
might allow to identify the link with phenotypic traits 
related to virulence, amplification, transmissibility to 
Figure 1
Cumulative number of human cases of West Nile virus infection in Europe and neighbouring countries, 2010 to 2013
Data source: European Centre for Disease Prevention and Control (ECDC).
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mosquitoes, and/or persistence, expressed in infected 
birds. Studies in avian models of WNV infection began 
in the US shortly after the first occurrence of WNV 
cases in 1999, and identified passerines as the group 
of birds developing higher and longer viraemias [66]. 
In contrast, studies testing the effect of European WNV 
strains in bird species indigenous to Europe have only 
been started recently [67-69].
Table 2 lists widely recognised genetic changes asso-
ciated with virulence/attenuation, confirmed by viral 
cDNA clone mutagenesis/chimeras and using animal 
models of WNV infection [70-78]. Point mutations 
leading to amino acid changes either in structural 
(E) or non-structural (NS2A, NS3, NS4B) proteins 
result in attenuated phenotypes in different models. 
Pathogenicity appears also to be influenced by changes 
at both 5’ and 3’ non-coding regions. Interestingly, the 
WNV genome is relatively flexible as it can tolerate a 
number of changes in its sequence that do not seem to 
affect pathogenicity. However, generalisation of these 
findings could be misleading. The spectrum of WNV 
strains to which they can be applicable needs to be 
defined, as the phenotypic effect of each of the changes 
described for one given strain might not affect all WNV 
strains equally. Care should be exercised not to extend 
blindly the results observed in a given model to other 
susceptible species. For instance, the T249P mutation 
at the NS3 increases pathogenicity of a Kenyan WNV 
L1a strain for American crows (Corvus brachyrhynchos), 
and the opposite mutation reverts the high pathogenic-
ity observed for the NY99 WNV strain in this species. 
However, this effect applies for American crows and 
not for house sparrows [79]. Moreover, Mediterranean 
WNV L1a strains with the NS3249P genotype did not 
show higher pathogenicity than their NS3249T counter-
parts either in mice [80], in the red-legged partridge 
(a bird species indigenous to southern Europe) [67], 
and in the house sparrow [68], although it has been 
recently shown that this mutation can modulate WNV 
pathogenicity of certain Mediterranean WNV strains for 
the European corvid, Corvus corone (carrion crow) [81]. 
Interestingly, the Greek WNV lineage 2 strains from the 
outbreaks in 2010 and 2011, involving human morbid-
ity and mortality, have been shown to bear the NS3249P, 
contrary to their likely precursors from central Europe 
and the WNV strains that caused outbreaks in Serbia 
and in Italy, which have a histidine residue instead of 
proline at this site [58]. Despite suggestive, the asso-
ciation between the high pathogenicity observed in 
human outbreaks and the presence of NS3249P in these 
Greek lineage 2 WNV strains need to be assessed 
experimentally. Also, phenotypic assessment of WNV 
strains should not be limited to pathogenicity but 
should take in consideration other phenotypic traits, 
such as host competence (capacity of a given host 
species to transmit the virus efficiently to a mosquito 
feeding on its blood)/transmissibility. Variations in 
host competence have been reported for different WNV 
strains in the house sparrow [68,69], which might help 
to explain, at least in part, the different epidemiologi-
cal patterns observed in the New versus the Old World.
Table 1
Overview of West Nile virus lineages and suggested lineage numbering
Suggested 
lineage 
numbering
Other lineage 
labelling in the 
literature
Representative strain
GenBank 
accession 
number
Note Reference
Lineage 1a Lineage 1 NY99-flamingo382-99, New York, 1999 AF196835 Most widespread WNV lineage
Lanciotti et al., 1999 
[115]
Lineage 1b Lineage 1 Kunjin MRM61C, Australia, 1960 D00246 Kunjin virus strains, Australia Coia et al., 1988 [116]
Lineage 1c Lineage 5 804994, India 1980 DQ256376 Only found in India Bondre et al., 2007 [117]
Lineage 2 No B956, Uganda 1937 (oldest WNV strain; WNV prototype strain) AY532665
Second most widespread WNV 
lineage
Smithburn et. al, 1940 
[118]
Lineage 3 No Rabensburg virus 97-103, Czech Republic 1997 AY765264 Only found in central Europe Bakonyi et al. [6]
Lineage 4a Lineage 4 LEIV-Krnd88-190, Russia 1998 AY277251 Originally isolated from Dermacentor ticks Lvov et al. [7]
Lineage 4b Lineage 6 / Lineage 7 HU2925/06, Spain GU047875 Only partial sequence available Vázquez et al. [8]
Lineage 4c Lineage 9 WNV-Uu-LN-AT-2013, Austria 2013 KJ831223
Identified in Uranotaenia 
mosquitoes Pachler et al. [9]
Lineage 5 Lineage 6 Kunjin virus KUN MP502-66, Malaysia 1966
GU047874, 
HQ840762
Only partial sequences 
available Vázquez et al. [8]
Lineage 6 Lineage 7 Dak Ar D 5443, Senegal EU082200 Koutango virus NA
Lineage 7 Lineage 8 ArD94343, Senegal 1992 KJ131502 Only partial sequence available Fall et al. [10]
NA: not available; WNV: West Nile virus.
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Figure 2a
Suggested harmonised West Nile virus lineage numbering based on phylogenetic analysisa
ClustalW alignments were conducted using BioEdit Sequence Alignment Editor (version 7.0.9.0). Phylogenetic neighbour-joining trees 
were generated with MEGA5 software [114], using 1,000 replicates for bootstrap testing, and evolutionary distances computation with the 
p-distance model. Bootstrap values less than 50% are hidden. The suggested new lineage numbering is indicated (in brackets other lineage 
designations previously used in literature are shown). In Figure 2A the phylogenetic tree was constructed on the basis of the complete 
polyprotein-encoding nucleotide sequences of 29 WNV strains including representatives of all WNV lineages for which complete polyprotein-
encoding nucleotide sequences have been available. In Figure 2B the phylogenetic tree was constructed on the basis of 799 bp fragments 
within the NS5 gene, which enabled inclusion of the Malaysian Kunjin virus isolate GU047874 and the Spanish WNV strain GU047875, as well 
as eight selected WNV strains representing other WNV lineages. In Figure 2C the phylogenetic tree was constructed on the basis of 1502 bp 
fragments within the envelope glycoprotein gene, which enabled inclusion of the Senegalese WNV isolate KJ131502 as well as 8 selected WNV 
strains representing other WNV lineages.
a  Other lineage labelling in the literature is given between brackets.
KF179640, WNV strain Austria/2008_gh
HQ537483, WNV isolate Nea Santa-Greece-2010
DQ116961, WNV isolate goshawk-Hungary/2004
EF429197, WNV strain SPU116/89, South Africa, 1989
AY532665, WNV strain B956, Uganda, 1937
HM147824, WNV, Democratic Republic of Congo, 1958
DQ318020, WNV strain ArB3573/82, Central African Republic, 1982
KJ934710, WNV strain Hyalomma/Romania/2013
FJ425721, WNV isolate Reb_VLG_07_H, Russia, 2007
HM147823, WNV, Madagascar, 1988
AY688948, WNV strain Sarafend
DQ176636, strain Madagascar-AnMg798, 1978
lin. 2
lin. 1c (lin. 5)DQ256376, WNV strain 804994, India, 1980
lin. 1bD00246, Kunjin virus strain MRM61C, Australia
AY490240, WNV strain Chin-01, China
AY603654, WNV strain EthAn4766, Ethiopia
AF196835, WNV strain NY99-flamingo382-99, USA, 1999
AF481864, WNV strain IS-98 STD1, Israel, 1998
DQ118127, WNV isolate goose-Hungary/2003
AY278441, WNV isolate Ast99-901, Russia, 1999
KF647253, WNV strain Italy/2013/Livenza/35.1
AF404757, WNV isolate WN Italy 1998-equine
AY278442, WNV isolate LEIV-Vlg00-27924, Russia, 2000
AF260969, WNV strain RO97-50, Romania, 1996
lin. 1a
lin. 6 (lin. 7)EU082200, Koutango virus strain Dak Ar D 5443, Senegal
lin. 3AY765264, Rabensburg virus isolate 97-103, Czech Republic, 1997
lin. 4c (lin. 9)KJ831223, WNV strain Uu-LN-AT-2013, Austria, 2013
AY277251, WNV isolate LEIV-Krnd88-190, Russia, 1998
FJ159129, WNV isolate 101_5-06-Uu, Russia, 2006
lin. 4a (lin. 4)
100
100
100
100
100
85
100
100
100
100
100
100
99
80
80
100
100100
99
97
100
100
100
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95
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Figure 2b
Suggested harmonised West Nile virus lineage numbering based on phylogenetic analysisa
ClustalW alignments were conducted using BioEdit Sequence Alignment Editor (version 7.0.9.0). Phylogenetic neighbour-joining trees 
were generated with MEGA5 software [114], using 1,000 replicates for bootstrap testing, and evolutionary distances computation with the 
p-distance model. Bootstrap values less than 50% are hidden. The suggested new lineage numbering is indicated (in brackets other lineage 
designations previously used in literature are shown). In Figure 2A the phylogenetic tree was constructed on the basis of the complete 
polyprotein-encoding nucleotide sequences of 29 WNV strains including representatives of all WNV lineages for which complete polyprotein-
encoding nucleotide sequences have been available. In Figure 2B the phylogenetic tree was constructed on the basis of 799 bp fragments 
within the NS5 gene, which enabled inclusion of the Malaysian Kunjin virus isolate GU047874 and the Spanish WNV strain GU047875, as well 
as eight selected WNV strains representing other WNV lineages. In Figure 2C the phylogenetic tree was constructed on the basis of 1502 bp 
fragments within the envelope glycoprotein gene, which enabled inclusion of the Senegalese WNV isolate KJ131502 as well as 8 selected WNV 
strains representing other WNV lineages.
a  Other lineage labelling in the literature is given between brackets.
lin. 1aAF196835, WNV strain NY99-flamingo382-99, USA, 1999
lin. 1bD00246, Kunjin virus strain MRM61C, Australia
lin. 1c (lin. 5)DQ256376, WNV strain 804994, India, 1980
lin. 5 (lin. 6)GU047874, Kunjin virus isolate KUNMP502-66, Malaysia, 1966
lin. 2AY532665, WNV strain B956, Uganda, 1937
lin. 3AY765264, Rabensburg virus isolate 97-103, Czech Republic, 1997
lin. 6 (lin. 7)EU082200, Koutango virus strain Dak Ar D 5443, Senegal
lin. 4a (lin. 4)AY277251, WNV isolate LEIV-Krnd88-190, Russia, 1998
lin. 4b (lin. 6 / lin. 7)GU047875, WNV isolate HU2925/06, Spain, 2006
lin. 4c (lin. 9)KJ831223, WNV strain Uu-LN-AT-2013, Austria, 2013
100
68
81
61
58
0.02
Figure 2c
Suggested harmonised West Nile virus lineage numbering based on phylogenetic analysisa
ClustalW alignments were conducted using BioEdit Sequence Alignment Editor (version 7.0.9.0). Phylogenetic neighbour-joining trees 
were generated with MEGA5 software [114], using 1,000 replicates for bootstrap testing, and evolutionary distances computation with the 
p-distance model. Bootstrap values less than 50% are hidden. The suggested new lineage numbering is indicated (in brackets other lineage 
designations previously used in literature are shown). In Figure 2A the phylogenetic tree was constructed on the basis of the complete 
polyprotein-encoding nucleotide sequences of 29 WNV strains including representatives of all WNV lineages for which complete polyprotein-
encoding nucleotide sequences have been available. In Figure 2B the phylogenetic tree was constructed on the basis of 799 bp fragments 
within the NS5 gene, which enabled inclusion of the Malaysian Kunjin virus isolate GU047874 and the Spanish WNV strain GU047875, as well 
as eight selected WNV strains representing other WNV lineages. In Figure 2C the phylogenetic tree was constructed on the basis of 1502 bp 
fragments within the envelope glycoprotein gene, which enabled inclusion of the Senegalese WNV isolate KJ131502 as well as 8 selected WNV 
strains representing other WNV lineages.
a  Other lineage labelling in the literature is given between brackets.
lin. 1aAF196835, WNV strain NY99-flamingo382-99, USA, 1999
lin. 1bD00246, Kunjin virus strain MRM61C, Australia
lin. 1c (lin. 5)DQ256376, WNV strain 804994, India, 1980
lin. 2AY532665, WNV strain B956, Uganda, 1937
lin. 3AY765264, Rabensburg virus isolate 97-103, Czech Republic, 1997
lin. 6 (lin. 7)EU082200, Koutango virus strain Dak Ar D 5443, Senegal
lin. 7 (lin. 8)KJ131502, WNV isolate ArD94343, Senegal, 1992
lin. 4a (lin. 4)AY277251, WNV isolate LEIV-Krnd88-190, Russia, 1998
lin. 4c (lin. 9)KJ831223, WNV strain Uu-LN-AT-2013, Austria, 2013100
100
98
54
0.02
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Diagnosis
The laboratory diagnosis of acute WNV infection is 
based on both the detection of WNV RNA in blood and 
cerebrospinal fluid (CSF) or virus isolation in cell cul-
ture from serum samples (direct diagnosis) and on the 
demonstration of a specific immune response against 
the virus (indirect diagnosis), recently reviewed by [82] 
and [83].
Detection of viral RNA
Detection of WNV RNA in biological specimens rep-
resents a rapid method to unambiguously prove the 
infection with WNV [84]. Different PCR-based proto-
cols have been developed to amplify minimal amounts 
of WNV RNA [85]. However, viraemia is short-lived in 
dead-end hosts and already declining substantially 
once the symptoms begin. Hence, detection of viral 
genomes becomes increasingly challenging over time. 
As a consequence, WNV RNA is generally not detect-
able in the blood of patients with symptomatic infec-
tion [86]. Additionally highly sensitive nucleic acid 
amplification-based methods may rarely provide false-
positive results by cross-reaction with other flavivi-
ruses [87]. Figure 3 delineates a timeline of clinical and 
diagnostic markers during human WNV infection.
Recent data demonstrated that WNV RNA can be 
detected in urine much longer and at higher concentra-
tions than in blood or CSF in individuals with WNF or 
WNND [86,88]. The duration of WNV RNA detection in 
urine seems dependent on the course of disease and 
could last for 20 days or longer [86].
Similar results were observed in experimentally 
infected monkeys and hamsters [89,90]. The virus 
excreted in urine is infectious, since it can be isolated 
in cell culture from urine specimens collected from 
patients with acute infection [91].
Implementation of WNV RNA testing and isolation from 
urine samples in routine protocols for WNV diagnosis 
demonstrated the utility of these tests for the confir-
mation of cases [30,86,88,91]. Although PCR methods 
have been developed to detect both major WNV line-
ages [92], a first external quality assessment (EQA) 
study in 2006, revealed that many laboratories had 
problems in detecting genomes of WNV lineage 2 [93], 
an issue of high concern since lineage 1 and 2 viruses 
are co-circulating in Europe. In a recent second EQA in 
2011, the participating laboratories had improved sig-
nificantly regarding this aspect [87]. PCR multiplexing 
can be useful in this respect, and recently a multiplex 
PCR method able to detect and differentiate WNV line-
ages 1 and 2 and USUV has been developed [94]. It is 
also essential that current PCR methods are constantly 
being checked and updated for their sensitivity and 
suitability to detect newly emerging WNV strains to 
cope with the observed genetic variability of European 
WNV strains.
Antibody detection
Antibodies against WNV start to appear about four to 
seven days following infection and IgM antibodies are 
already detectable at early time points after symptoms 
onset [86] (Figure 3). Thus, the diagnosis of WNV infec-
tion generally relies on the demonstration of specific 
antibodies against WNV in serum or CSF.
The major problem with most serological diagnostic 
tests for WNV is cross-reactivity with infections caused 
by other flaviviruses, and the last EQA on WNV serology 
organised by the European Network for Diagnostics of 
Imported Viral Diseases (ENIVD) also showed the limits 
and needs for improvement [95]. Therefore, consider-
able effort is being made to develop antigens and/or 
test formats which can be used for specific detection of 
anti-WNV antibodies [reviewed in 83]. These also have 
to take into consideration the heterogeneity of human 
antibody profiles to WNV infection [96]. Furthermore, 
several flaviviruses have been found in areas affected 
by WNV, including BAGV, tick-borne encephalitis virus 
TBEV , and USUV [22,53,97,98].
Taking into account these problems, the European 
Union case definition for WNV infections demands con-
firmation in cases with IgM detection in serum by virus 
neutralisation test (VNT) [99], which today is the gold 
standard diagnostic method for flavivirus serology 
(reviewed in [83]). However, VNTs are time-consum-
ing and require a biosafety level (BSL)-3 laboratory. 
Monoclonal antibody panels with strong and specific 
reactivity to TBEV, USUV and WNV were recently devel-
oped [100], which will likely enable the development of 
improved immunoassays for the detection and differ-
entiation of flavivirus infections. Furthermore, mono-
clonal antibodies could be used for the development 
of competitive tests for the detection of different types 
of anti-WNV antibodies suitable for the range of WNV 
host species, including many species of wild birds and 
susceptible mammals [101]. Alternatively, the use of 
mutant forms of viral proteins leads to a minimisation 
of antibody cross-reactivity and enables the serologi-
cal differentiation of flavivirus infections [102].
Vaccines
The persistent long-term effects seen after resolution 
of acute WNV infection in humans, the emerging threat 
that WNV poses to Europe and the placement of WNV 
on the list of bioterrorism agents, makes the develop-
ment of a safe and effective vaccine for humans an 
urgent priority [103]. In fact, while several vaccines are 
already available for horses [104-106] and other cur-
rently under development due to the impact of WNV 
infection on the horse industry, no vaccine is available 
for humans.
Towards the production of a human vaccine
The increasing understanding of WNV pathogenesis 
and correlates of protection in animal models pave 
the way to a more rational design of candidate vac-
cines. Studies performed in mice elucidated some of 
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the mechanisms of protection, such as the role of the 
adaptive immune responses in mitigating and prevent-
ing development of disease. This is exemplified by the 
observation that transfer of WNV-specific antibodies to 
naïve mice protected the animals against development 
of severe neurological disease [107]. Several lines of 
evidence indicate that the B cell response after infec-
tion with WNV is predominantly directed to non-neutral-
ising epitopes located in domain I and II of glycoprotein 
E. The most potent neutralising epitopes are located in 
domain III (the receptor-binding ligand). For the devel-
opment of a WNV vaccine for humans it is important 
to understand how vaccination could increase the lon-
gevity of B cells that produce these potent neutralis-
ing antibodies. As the probability of neuroinvasion in 
the animal host appeared to correlate with the level 
and duration of viraemia, it is conceivable that persis-
tence of neutralising antibodies is sufficient to protect 
against severe disease [108]. Although T cells play a 
role in eliminating an established infection, thereby 
reducing the antigen load, it is believed that antibod-
ies are more important for vaccine-induced protection. 
It is worth noting that both CD4+ and CD8+ T cells have 
been shown to contribute to control of WNV infection 
in animal models but it cannot be excluded that T cells 
may also cause disease [109].
Several platforms have been used to develop candi-
date vaccines against WNV for humans [109]. Various 
vaccine candidates have been shown to be highly 
effective in preventing fatal disease in mice and horses 
[110-112]. Long-term immunogenicity and safety, how-
ever, are some of the most important problems in cur-
rent veterinary vaccines against WNV and potential 
candidates for use in humans. The regulatory authori-
ties as well as public opinion demand safe and well 
characterised vaccines. Therefore, an effective WNV 
vaccine should stimulate protective and long-term 
immunity, preferably after a single dose, and should be 
free of significant side effects, especially in the elderly 
and immunocompromised individuals. Research on the 
use of several platforms for development of a safe and 
effective vaccine against WNV lineages 1 and 2 was 
an important topic in several European consortia and 
yielded promising candidate approaches.
Knowledge gaps and research priorities
Although significant progress in the scientific knowl-
edge on WNV in Europe has been made through pro-
jects funded by the FP7, several knowledge gaps still 
limit our ability to properly forecast changes in the 
risks of outbreaks to occur or to prevent and control 
virus transmission to humans and animals.
Knowledge gaps on the introduction and 
spread of WNV in Europe 
Our knowledge on how, when and from where WNV is 
introduced into Europe is still very limited today. The 
role of migrating birds on WNV translocations is recog-
nised, however, many important questions still remain 
unanswered e.g. the geographic origin of each intro-
duction of WNV into Europe, the relative importance 
of the introduction of infected vectors rather than 
infected birds, and the detailed transmission mecha-
nisms involved in virus establishment into new  areas. 
For these reasons, better knowledge on the WNV ecol-
ogy, vectors and virus strains circulating currently in 
Africa will be of utmost importance. Key factors lead-
ing to virus amplification and spread to neighbouring 
areas are also essentially unknown. Furthermore, we 
know that the virus may disappear from a previously 
infected area but we ignore the key factors leading to 
Table 2
Non-exhaustive list of genetic determinants of West Nile virus pathogenicity identified in animal models
Genome 
region Genetic change Phenotypic effect(s)/mechanism(s) involved
Phylogenetic 
group
Animal model 
used
Experimental 
system References
E
Various, on the 
154-NYS(T)-156 
(N-glycosylation) 
motif
N-glycosylation site abolished; unstable E-peptide fusion; 
decreased viral replication.
Lineages 1 
(clades a and 
b) and 2
Mice cDNA clone mutagenesis [70,71]
NS2A A30P NS1’ (NS1 extension) abolished; disruption of NS1-mediated immune evasion mechanisms.
Kunjin 
(Lineage 1, 
clade b)
Mice cDNA clone mutagenesis [72,73]
NS3 T249P Increased virogenesis, efficient replication at higher temperatures.
Lineage 1, 
clade a American crow
cDNA clone 
mutagenesis [74]
NS4B
C102S
P38G
E249G
Abrogation of evasion from host innate immunity (IFN 
α/β response); decreased helicase activity (decreased 
virus replication).
Lineage 1 
clade a Mice
cDNA clone 
mutagenesis [75,76]
3’UTR Unknown sfRNA abrogation. Lineage 1, clade b Mice
cDNA clone 
mutagenesis [77]
5’UTR 5-AAT/TTG-52 Unknown
Lineage 1, 
clades a 
and b
Mice
cDNA clone 
mutagenesis 
and chimeras
[78]
WNV: West Nile virus. 
The list represents widely recognised genetic changes associated with WNV virulence/attenuation that have been shown to occur in natural 
WNV isolates.
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its extinction. Spillover events are increasing in num-
bers and expand geographically over time in Europe, 
however, our knowledge on the factors triggering such 
events continues to be rather poor. We do not know 
in most cases which are the key amplifying bird host 
and the bridge vector species involved. Moreover, we 
do not know the consequences of interventions such 
as massive culling of species considered as ‘pests’ 
and the contribution of factors such as species com-
munity composition under variable climatic and envi-
ronmental conditions at local level. With this level of 
eco-epidemiological uncertainty, building-up accurate 
predictive models of WNV outbreak risk is a complex 
undertaking, although progress has been made in this 
direction [46,47,113]. Epidemiological models rely on 
good knowledge on basic epidemiological information 
of the virus and the disease it causes, which is still 
lacking in many cases, as outlined above. Filling this 
gap will not be an easy task; for instance, competence 
for WNV transmission of each host and vector species 
must be calculated experimentally for each viral strain, 
but given the heterogeneity of WNV found in Europe, 
this work will require a huge effort even if restricted 
to few representative strains and host/vector species.
Knowledge gaps on the impact of the presence 
of other flaviviruses on WNV epidemiology
Another important knowledge gap is the impact that 
other co-circulating flaviviruses (and perhaps arbo-
viruses) may have on WNV epidemiology in Europe. 
Cross-immunity between closely related flaviviruses 
might lead to some degree of cross-protection in the 
animal hosts, or, even enhance infection in certain 
cases. Further assessment of the consequences of 
viral interference on the immune response both in 
hosts and vectors in Europe is needed. Realistic WNV 
models should also incorporate these effects. The 
diversity of flaviviruses circulating in Europe, including 
mosquito-only flaviviruses as well as newly emerging 
flavivirus strains, represent another challenge for WNV 
research. Europe’s preparedness to face emerging fla-
vivirus threats depends largely on the availability of 
large datasets integrating genomic characterisation 
and analysis of all the strains isolated in Europe and 
neighbouring areas, including Africa. These datasets, 
together with the already started bank of viral strains, 
will be of paramount importance for the development 
of efficient molecular tools enabling proper flavivi-
rus detection, identification and classification, along 
with studies on the origins of the different flaviviruses 
emerging in Europe and their evolutionary history.
Knowledge gaps on mosquito control
There is a need to strengthen the entomological 
capacity in Europe to improve surveillance, and risk 
assessment, and to identify the most appropriate and 
environmental friendly control strategies especially 
within hot spots of arbovirus emergence and spread 
in the Old World. The number of products available for 
mosquito control has been reduced in recent years. 
New insecticides and repellents are urgently needed 
since those available are losing efficacy. There is a 
clear need to define and evaluate the effectiveness of 
integrated mosquito control strategies and involve the 
public in mosquito source reduction. Models to sup-
port decision in mosquito control and management are 
also urgently required.
Knowledge gaps on the identification of 
virulence factors
Virus strain characterisation, in particular, virulence 
studies and identification of virulence determinants 
demand proper experimental animal models. Rodents 
(mice, hamsters) used as surrogate incidental mammal 
host model still need some standardisation and the 
same applies to wild birds, used as susceptible, res-
ervoir and amplification host models useful to obtain 
data on virus pathogenicity and transmission. Suitable 
animal models would not only constitute an invaluable 
tool for virus characterisation, but also enable stud-
ies on co-infection, cross-protection, vaccine efficacy, 
therapeutic testing, the effect of stress and immuno-
suppression during the course of infection, among 
others.
Knowledge gaps on laboratory detection
The challenge in diagnostics is the WNV diversity in 
Europe and the need to continuously check the effec-
tiveness of existing laboratory tests for the detection 
of newly arising strains or antibodies to them. This 
requires a considerable effort from all WNV diagnostic 
laboratories involved. The main gap in WNV serology 
is to develop new generation immunoassays avoiding 
cross-reactions with different flaviviruses and enabling 
good flavivirus differentiation, minimising the need 
for confirmation by the gold standard VNT. For that, 
large panels of well-characterised monoclonal anti-
bodies to different flaviviral epitopes would be invalu-
able. Development of markers of early/mature immune 
response is also desirable. In the veterinary field, sero-
logical tests differentiating infected from vaccinated 
Figure 3
Viraemia and humoral immune responses against West 
Nile virus
-5 50 10 15 20 25 30
IgG
IgM
viremiaVira
Viral RNA in urine
Vi
ra
em
ia
 a
nd
 h
um
or
al
 re
sp
on
se
Days after/before symptoms onset
11www.eurosurveillance.org
individuals are largely awaited. Where possible, inclu-
sion of different types of antigens in the immunoassays 
would help to avoid false negative results due to het-
erogeneity of the humoral immune responses to WNV. 
In molecular diagnostics, new methods enabling rapid 
differential diagnosis of flavivirus infections, prefer-
ably in multiplex formats, are needed. New samples 
for virus detection and isolation (for instance, urine 
in humans, or feathers in wild bird surveillance) need 
further validation to assess their impact on diagnostic 
sensitivity and specificity, also, when possible, with 
different WNV strains.
Knowledge gaps on therapy and prevention
The lack of specific treatment and of human vaccines 
constitutes another gap in the mitigation of WNND. 
Together with the high susceptibility of the elderly, this 
renders the disease of great societal impact because 
of the ageing of the European population. The spread 
of WNV, even in the absence of clinical cases of WNND, 
imposes a significant economic burden for European 
public health due to the need to guarantee blood and 
organ transplantation safety. 
Gaps in vaccine development include safety issues, 
especially in target susceptible populations such as 
the elderly and immunocompromised individuals. 
Due to the unpredictable regional spread of WNV out-
breaks, clinical effectiveness testing of WNV vaccines 
in humans seems difficult. In combination with the yet 
limited market size, this has so far prevented further 
development of vaccine candidates by the pharmaceu-
tical industry. Therefore, in order to move one or more 
of the existing (and promising) candidate vaccines 
towards clinical development, there needs to be a joint 
evaluation between industry, researchers and regula-
tory authorities. The possible interactions with other 
available flavivirus vaccines in Europe such as the 
ones against TBE and yellow fever virus (the latter only 
used for travellers to endemic areas outside Europe), 
and interactions with infections by other related fla-
viviruses, including cross-protection and/or antibody-
dependent enhancement of infection, need further 
clarification.
Conclusion
The unpredictability of the West Nile virus risk for 
Europe and neighbouring countries is strongly linked 
to the knowledge gaps on many aspects of its com-
plex ecology, genomic diversity, pathogenicity, trans-
missibility, diagnosis and control options, under 
different environmental and socio-economic scenarios. 
Therefore, there is an urgent need to intensify and con-
tinue the research efforts on WNV and other emerging 
vector-borne infections built under the FP7. In parallel, 
there is a growing need for a unified, harmonised, real-
time epidemiological surveillance of WNV in vectors, 
humans and animals, especially within hot spots of 
virus circulation in Europe under the guidance of ECDC 
and other international organisations.
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